Sandu Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "42.22",
    "chg": -0.68,
    "chgp": "-1.59%",
    "dir": -1,
    "prev_price": "42.90",
    "mcapval": "41.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "India SENSEX",
    "isin": "INE751D01014",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "712 ",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3987314",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SanduPharmaceut_mojoScore_3987314.png",
        "date": "2026-05-12 10:10:46",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "When is the next results date for Sandu Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-sandu-pharmaceuticals-ltd-3967217",
        "imagepath": "",
        "date": "2026-04-28 23:16:14",
        "description": "The next results date for Sandu Pharmaceuticals Ltd is scheduled for 05 May 2026...."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-concerns-3965424",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_valuationdot_3965424.png",
        "date": "2026-04-28 08:01:26",
        "description": "Sandu Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from fair to expensive territory, raising questions about its price attractiveness relative to historical levels and peer benchmarks. Despite recent gains in share price, the company’s micro-cap status and deteriorating mojo grade to a strong sell underscore investor caution amid stretched multiples."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3958955",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_mojoScore_3958955.png",
        "date": "2026-04-23 10:10:41",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Sep 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-to-fair-amid-mixed-market-returns-3943855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_valuationdot_3943855.png",
        "date": "2026-04-13 08:00:51",
        "description": "Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 0.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment, raising questions about its price attractiveness relative to historical and peer benchmarks."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3941430",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_mojoScore_3941430.png",
        "date": "2026-04-10 10:10:44",
        "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3933647",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_valuationdot_3933647.png",
        "date": "2026-04-06 08:00:56",
        "description": "Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This change, driven primarily by improvements in price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Weak Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-to-fair-amidst-weak-market-performance-3923329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SanduPharmaceut_valuationdot_3923329.png",
        "date": "2026-03-30 08:01:25",
        "description": "Sandu Pharmaceuticals Ltd has seen its valuation parameters adjust from attractive to fair, reflecting a nuanced shift in investor sentiment amid a challenging market backdrop. Despite a recent downgrade to a Strong Sell rating, the company’s price-to-earnings and price-to-book ratios suggest a more balanced valuation compared to its historical averages and peer group, signalling a complex investment case for stakeholders."
      },
      {
        "title": "Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Challenging Market Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-to-fair-amidst-challenging-market-returns-3909052",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SanduPharmaceut_valuationdot_3909052.png",
        "date": "2026-03-24 08:01:25",
        "description": "Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, warrants a detailed analysis to understand its implications for investors amid a challenging market backdrop."
      }
    ],
    "total": 10,
    "sid": "764862",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Jun-2026",
      "details": "Newspaper Publication for opening of special window for re lodgment of transfer requests for physical shares and Second 100 days campaign Saksham Niveshak creating awareness amongst shareholders to update KYC Details and for shareholders engagement to prevent transfer of unpaid/unclaimed dividends to investor Education and Protection Fund (IEPF)",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "18-May-2026",
      "details": "Annual Secretarial Compliance Report for Year ended 31st March 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30-Update Demand Order From Office Of Assistant Commissioner Jurisdiction Sector 3 (Mobile Squad-1) Shamli State/UT Uttar Pradesh For Detention Of Conveyance & Goods Due To Discrepancy In Quantity As Per Invoice & Quantity As",
      "datetime": "07-May-2026",
      "details": "Demand order from office of assistant commissioner due to discrepancy in quantity as per invoice and quantity as per physical verification of Goods",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-05-12 10:10:46

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

When is the next results date for Sandu Pharmaceuticals Ltd?

2026-04-28 23:16:14

The next results date for Sandu Pharmaceuticals Ltd is scheduled for 05 May 2026....

Sandu Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Concerns

2026-04-28 08:01:26

Sandu Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from fair to expensive territory, raising questions about its price attractiveness relative to historical levels and peer benchmarks. Despite recent gains in share price, the company’s micro-cap status and deteriorating mojo grade to a strong sell underscore investor caution amid stretched multiples.

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-04-23 10:10:41

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Sep 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Returns

2026-04-13 08:00:51

Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 0.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market sentiment, raising questions about its price attractiveness relative to historical and peer benchmarks.

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-04-10 10:10:44

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-04-06 08:00:56

Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This change, driven primarily by improvements in price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Weak Market Performance

2026-03-30 08:01:25

Sandu Pharmaceuticals Ltd has seen its valuation parameters adjust from attractive to fair, reflecting a nuanced shift in investor sentiment amid a challenging market backdrop. Despite a recent downgrade to a Strong Sell rating, the company’s price-to-earnings and price-to-book ratios suggest a more balanced valuation compared to its historical averages and peer group, signalling a complex investment case for stakeholders.

Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Challenging Market Returns

2026-03-24 08:01:25

Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, warrants a detailed analysis to understand its implications for investors amid a challenging market backdrop.

View All News